Evaluation of the clinical efficacy of transurethral bipolar surgery and laser technologies in the treatment of patients with benign prostatic hyperplasia

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

BACKGROUND: Benign prostatic hyperplasia (BPH) is common middle-aged and elderly men. In modern urology, transurethral resection and its modifications are used in surgical treatment of BPH. In the last decades, an active tendency of laser technologies development in urology was noted. The search for the most appropriate techniques of transurethral removal of prostate adenoma by comparing the results of treatment of patients with the use of different technologies remains relevant.

AIM: This study aimed to evaluate the clinical effectiveness of transurethral bipolar surgery and laser technologies in the treatment of BPH.

MATERIALS AND METHODS: Transurethral enucleation of the prostate using various technologies was performed in 273 patients with BPH between 2021 and 2023: 94 patients underwent bipolar transurethral enucleation of the prostate, 87 underwent thulium enucleation of the prostate (ThuLEP), and 92 underwent holmium enucleation of the prostate (HoLEP).

RESULTS: Clinical evaluation showed the absence of intraoperative complications. For ThuLEP, a trend toward shorter operative times compared to other techniques was observed. In the early postoperative period, significant bleeding was noted in six cases of using bipolar technology, three cases of using a thulium laser, and five cases of using a holmium laser. An examination of patients 6 months postsurgery showed pronounced positive dynamics in all three groups. No significant differences were found in clinical parameters 6 months postsurgery in patients of different groups.

CONCLUSIONS: Bipolar enucleation of the prostate, ThuLEP, and HoLEP are comparable in effectiveness and the number of complications in the surgical treatment of BPH. Study results indicated that it is advisable to actively use these methods in wide clinical practice.

About the authors

Suleiman I. Suleimanov

People’s Friendship University of Russia; City Clinical Hospital No. 13

Author for correspondence.
Email: s.i.suleymanov@mail.ru
ORCID iD: 0000-0002-0461-9885
SPIN-code: 7168-8819
Scopus Author ID: 57080003900

MD, Dr. Sci. (Medicine)

Russian Federation, Moscow; Moscow

Alan M. Aguzarov

City Clinical Hospital No. 13

Email: aguzarofff@ya.ru

MD

Russian Federation, Moscow

Zaur I. Ashurov

City Clinical Hospital No. 13

Email: zaur_ashurov@mail.ru

MD

Russian Federation, Moscow

Aleksandr S. Babkin

City Clinical Hospital No. 13

Email: alexbabkin3004@mail.ru
ORCID iD: 0000-0003-1570-1793

MD

Russian Federation, Moscow

Konstantin K. Bagaturiya

City Clinical Hospital No. 13

Email: buba-190@rambler.ru

MD

Russian Federation, Moscow

Vladislav V. Musokhranov

City Clinical Hospital No. 13

Email: vlad412@mail.ru
ORCID iD: 0000-0003-1336-931X

MD, Cand. Sci. (Medicine)

Russian Federation, Moscow

Alexander A. Tyagun

City Clinical Hospital No. 13

Email: tyagun1976@gmail.com

MD

Russian Federation, Moscow

Dmitry A. Fedorov

City Clinical Hospital No. 13

Email: fedorov3867@icloud.com
ORCID iD: 0000-0002-6232-2078

MD

Russian Federation, Moscow

References

  1. Berry SJ, Coffey DS, Walsh PC, Ewing LL. The development of human benign prostatic hyperplasia with age. J Urol. 1984;132(3): 474–479. doi: 10.1016/s0022-5347(17)49698-4
  2. Park HJ, Won JEJ, Sorsaburu S, et al. Urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH) and LUTS/BPH with erectile dysfunction in Asian men: A systematic review focusing on Tadalafil. World J Mens Health. 2013;31(3):193–207. doi: 10.5534/wjmh.2013.31.3.193
  3. Zolotukhin OV, Esin AV, Madykin YuYu. Pathogenetic justification of the use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. Experimental and Clinical Urology. 2022;(3) 94–101. EDN: LCBERR doi: 10.29188/2222-8543-2022-15-3-94-101
  4. Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia. Urol Clin North Am. 2009;36(4):403–415. doi: 10.1016/j.ucl.2009.07.003
  5. Sevryukov FA, Sorokin DA, Karpukhin IV, et al. Transurethral enucleation of prostate (TUEB) — new option in bipolar endoscopic surgery of BPH. Experimental and Clinical Urology. 2012;(2):34–36. EDN: PDARMH
  6. Trushkin RN, Sysoev AM. Transurethral enucleation of prostate gland by bipolar loop — the first experience. Surgical practice. 2014;(4):41–43. EDN: TMQKIT (In Russ.)
  7. Kadyrov ZA, Suleymanov SI, Eremeishvili GM, et al. Extraperitoneal laparoscopic prostatectomy for benign prostatic hyperplasia in larger sizes. Andrology and genital surgery. 2012;13(3):19–24. EDN: PGOUEZ
  8. Enikeev DV, Glybochko PV, Alyaev YuG, et al. Laser enucleation of the prostate (HOLEP and THULEP): a comparative effectiveness analysis in treating recurrent prostatic hyperplasia. Urologiia. 2017. № 4. С. 50–54. EDN: ZFVHRJ doi: 10.18565/urol.2017.4.50-54
  9. Enikeev DV, Glybochko PV, Alyaev YuG, et al. Current laser technologies for the surgical treatment of prostatic hyperplasia. Urologiia. 2017;(1):108–113. EDN: YJAMHR doi: 10.18565/urol.2017.1.108-113
  10. Shoma AM, Ghobrial FK, El-Tabey N, et al. A randomized trial of holmium laser vs thulium laser vs bipolar enucleation of large prostate glands. BJU Int. 2023;132(6):686–695. doi: 10.1111/bju.16174
  11. Chen J, Dong W, Gao X, et al. A systematic review and meta-analysis of efficacy and safety comparing holmium laser enucleation of the prostate with transurethral resection of the prostate for patients with prostate volume less than 100 mL or 100 g. Transl Androl Urol. 2022;11(4):407–420. doi: 10.21037/tau-21-1005
  12. Gilling PJ, Cass CB, Cresswell MD, Fraundorfer MR. Holmium laser resection of the prostate: preliminary results of a new method for the treatment of benign prostatic hyperplasia. Urology. 1996;47(1):48–51. doi: 10.1016/s0090-4295(99)80381-1
  13. Herrmann TR, Bach T, Imkamp F, et al. Thulium laser enucleation of the prostate (ThuLEP): transurethral anatomical prostatectomy with laser support. Introduction of a novel technique for the treatment of benign prostatic obstruction. World J Urol. 2010;28(1):45–51. doi: 10.1007/s00345-009-0503-0
  14. Enikeev DV, Glybochko PV, Alyaev YuG, et al. Comparative analysis of the effectiveness of various techniques of endoscopic prostate enucleation in a single center. Pirogov Russian Journal of Surgery. 2017;(11):4–14. EDN: ZTTLZP doi: 10.17116/hirurgia2017114-14

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2024 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ №ФС77-65570 от 04 мая 2016 г.


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies